Poly dimethyl siloxane (silicone oil) has remained a very useful internal tamponading agent for repairing complex retinal detachments. Despite the extensive list of complications described with the long-term use of this agent, [1] its use has not diminished, thanks to the inability to find better agents. Hence, surgeons always attempt to remove the oil at the earliest opportunity. Removal of oil is a major step in the overall management of the eye. In addition to removing the oil, it involves 1. Reducing the risk of recurrence of retinal detachment following the oil removal by appropriate maneuvers. 2. Managing epimacular membranes that often coexist 3. Managing secondary glaucoma that may coexist 4. Managing coexisting cataract.
Managing the lens in a phakic eye with silicone oil poses specific challenges. The May 2009 issue of IJO carried an article addressing the issue of refractive outcome after a single-step versus two-step approach for managing silicone oil filled eyes with cataract. [2] While managing a phakic eye with silicone oil, one may face the following permutations and combinations. In terms of functionality, the first three have more grave consequences than the improper refractive correction. However, for a patient who has good visual recovery and stable and good anatomical result from the retinal reattachment surgery, improper refractive outcome could be an important and annoying negative outcome.
From the retinologist's point of view, if one sees a stable retina following silicone oil removal with normal intra ocular pressure (IOP), the job is considered well done, even if the patient requires corrective glasses much more than expected. This article puts this issue in the perspective forcing the retinologist to rethink on the priorities and include poor refractive outcome as an important undesirable outcome in addition to the more complicated issues alluded to above.
Getting an accurate and reliable axial length measurement is the key issue in intra ocular lens (IOL) power calculation and this is thwarted by the presence of silicone oil. Ultrasound biometry (with adjustment of the speed of sound in vitreous cavity to 987 m/s) has been shown to be reasonably accurate with both 1,000 and 5,000 cst silicone oil. A deviation in final refraction of within two diopters was found in 72.4%. [3] This study has shown that error was more in eyes with greater axial length. Several studies have shown that the IOL master is more accurate in measuring axial length compared with the ultrasound-based A scan measurement in silicone oil filled eyes. [4] [5] [6] However, dense cataracts and poor fixation by patient can pose problems in getting accurate measurements even with IOL master. Poor fixation may not be an uncommon association in the circumstances of a silicone filled eye.
Considering the above, the following may be an acceptable approach when planning silicone oil removal with cataract surgery. 1. Measure axial length with IOL master when available and possible. If measurements are possible, one can proceed with combined surgery 2. If good measurements are possible and repeatable with ultrasound biometry, and if they correlate with known information (pre-op refractive error/fellow eye status, etc.), one can proceed with planned combined surgery 3. In known cases of high myopia (a not uncommon association with retinal detachments needing silicone oil tamponade), and where axial length measurements are not possible with both IOL master and ultrasound biometry, the following approach is reasonable: a. Where the lens opacity is not very dense (one should be able to judge the retinal status intraoperatively after removal of oil, as well as do additional procedures, such as membrane peeling, endolaser, etc.), it is best to do the cataract surgery a few weeks after removal of oil b. Where the cataract is dense and does not permit much of posterior segment surgery, it is best to remove the cataract, remove the oil, and perform additional posterior segment maneuvers as needed, but not place the IOL. One can keep the pupil mobile by using tropicamide or cyclopentolate once a day and at the earliest opportunity place a secondary IOL based on postoperative measurements for IOL power calculation. In most cases, one is only able to place the IOL in the sulcus since the capsular bag might not be open. On occasions, one may come across very highly myopic eyes that may become emmetropic or slightly myopic in the aphakic state and may not need IOL implantation. They may of course need early Yag capsulotomy since posterior capsule opacification will occur very fast in the absence of the IOL.
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Nil. in regional ophthalmic anesthesia
Regional anesthesia is the most common mode of anesthesia used in ophthalmic surgical procedures. Among regional blocks, peribulbar anesthesia is the safest and most commonly used. However, in procedures with prolonged operating time such as vitreoretinal surgeries, repeated need for block supplementation and patient anxiety are a challenge. Adjuvants to peribulbar anesthetics such as hyaluronidase and adrenaline along with preoperative anxiolytics/sedatives have been tried to overcome these challenges. [1] Alpha2 agonists are drugs that bind selectively to alpha2 adrenergic receptors in the central, peripheral, and autonomic nervous system as well as in vital organs and blood vessels. They produce dose-dependent analgesia, anxiolysis, and sedation without causing respiratory depression by acting on the G-protein-coupled alpha2 receptors. [2] Two main alpha2 agonists that are commercially available include clonidine and dexmedetomidine. Although neither of them is completely selective for alpha2 receptors, dexmedetomidine is 8-10 times more selective toward these receptors compared with clonidine. Dexmedetomidine has a higher avidity and affinity for alpha2 receptors, shorter elimination half-life, and higher clinical efficacy with a lesser side effect profile compared with clonidine. [3] The study by Gujral et al. adds credence to the anxiolytic effect of dexmedetomidine which is coupled with hemodynamic safety in patients receiving peribulbar block for vitreoretinal surgery. [4] Clonidine was the first alpha2 agonist to be used as an adjuvant by Mjahed et al., who found that its addition to peribulbar block decreased intraocular pressure, enhanced anesthesia, akinesia, and intraoperative sedation. [5] However, use of clonidine was associated with hemodynamic side effects such as bradycardia, arterial and orthostatic hypotension, rebound hypertension, and syncope. The long half-life of clonidine meant that the hemodynamic instability was not only seen intraoperatively but also for upto 8 h in the postoperative period. [6] Dexmedetomidine, a newer alpha2 agonist, has shown potential with a better safety profile due to its higher selectivity and shorter half-life. Two recent studies have evaluated its efficacy and side effect profile when used as an adjunct to peribulbar block during vitreoretinal surgery. [7, 8] Ahmed et al. [7] used 20 µg of dexmedetomidine along with lidocaine, bupivacaine, and hyaluronidase. They found faster onset of anesthesia, akinesia, increased duration of anesthesia, and increased patient sedation in comparison to a control group using normal saline. EL-Shmaa et al.
[8] compared two doses of dexmedetomidine -15 and 30 µg -as adjuvants to routine peribulbar anesthetic agents. They also found similar results in terms of onset and duration of anesthesia in the dexmedetomidine groups compared with the control group. The two doses did not differ significantly in terms of their efficacy or side effect profile. This study in contrast did not find any difference in the time of onset of anesthesia between the study and the control group; however, the patient and surgeon comfort was significantly better with dexmedetomidine. This study is also unique in keeping the systemic stability as its primary outcome measure. [4] No significant systemic side effects have been reported with either of the studies while using this drug in vitreoretinal surgeries.
There is increasing evidence that supports the use of dexmedetomidine as an adjunct to regional blocks for ophthalmic
